Aardvark Therapeutics (NASDAQ:AARD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Aardvark Therapeutics (NASDAQ:AARD) from a strong sell rating to a sell rating in a report published on Saturday.

Several other research analysts also recently weighed in on AARD. B. Riley Financial cut their price target on Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Morgan Stanley restated an “underweight” rating and issued a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a research note on Friday, May 15th. Weiss Ratings raised shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 2nd. BTIG Research lowered shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Finally, HC Wainwright reiterated a “neutral” rating and set a $6.00 target price on shares of Aardvark Therapeutics in a research report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Aardvark Therapeutics has a consensus rating of “Hold” and a consensus target price of $16.30.

Aardvark Therapeutics Trading Up 3.1%

NASDAQ:AARD opened at $6.74 on Friday. Aardvark Therapeutics has a 12 month low of $3.35 and a 12 month high of $17.94. The firm’s 50 day moving average is $5.71 and its 200 day moving average is $6.37. The stock has a market capitalization of $147.47 million, a PE ratio of -2.10 and a beta of 3.80.

Aardvark Therapeutics (NASDAQ:AARD) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.21. Research analysts predict that Aardvark Therapeutics will post -3.22 earnings per share for the current year.

Institutional Investors Weigh In On Aardvark Therapeutics

Several hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Aardvark Therapeutics in the 2nd quarter worth $42,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Aardvark Therapeutics during the 4th quarter worth $47,000. Persistent Asset Partners Ltd bought a new stake in shares of Aardvark Therapeutics during the 4th quarter worth $56,000. New York State Common Retirement Fund purchased a new position in Aardvark Therapeutics in the second quarter worth $99,000. Finally, MetLife Investment Management LLC purchased a new position in Aardvark Therapeutics in the fourth quarter worth $102,000.

Key Aardvark Therapeutics News

Here are the key news stories impacting Aardvark Therapeutics this week:

• Neutral Sentiment: Shareholders reportedly approved the company’s directors, auditor and an option-repricing proposal. The approvals reduce governance uncertainty, but the option repricing could raise dilution or compensation concerns. Aardvark Therapeutics Shareholders Approve Directors, Auditor and Option Repricing
• Neutral Sentiment: Analysts recently offered commentary on Aardvark, but the available report does not identify a specific price-target change or new recommendation likely to materially affect the shares. Analysts Offer Insights on Aardvark Therapeutics
• Negative Sentiment: Several investor-rights firms, including Hagens Berman, Robbins LLP, Rosen Law Firm, Kaplan Fox, Gainey McKenna and Holzer & Holzer, highlighted a securities class action filed against Aardvark. The case covers shares purchased in the February 2025 IPO and securities acquired between February 13, 2025, and May 14, 2026. The repeated notices may increase visibility of the litigation and weigh on investor sentiment. AARD Investor Alert: Class Action Lawsuit Filed
• Negative Sentiment: The complaint allegedly claims Aardvark’s registration statement and subsequent disclosures misrepresented the safety of ARD-101 and overstated the drug candidate’s clinical, regulatory and commercial prospects. These are allegations, not established findings, but they create potential legal costs, reputational damage and additional uncertainty around ARD-101. Investors seeking lead-plaintiff status generally face an October 13, 2026 deadline. AARD Investors Have Opportunity to Lead Securities Fraud Lawsuit

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.